Cellares, Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform
Portfolio Pulse from Benzinga Newsdesk
Cellares and Cabaletta Bio have partnered to evaluate automated manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy, on Cellares' Cell Shuttle Platform.
November 06, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cabaletta Bio has partnered with Cellares to evaluate automated manufacturing for its CD19-CAR T Cell Therapy, CABA-201. This could potentially streamline production and reduce costs.
The partnership with Cellares could potentially streamline the production process of Cabaletta's CABA-201 therapy, reducing costs and increasing efficiency. This could have a positive impact on Cabaletta's bottom line and therefore its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100